 Ajay Major
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 93 | 3.170 |
Why?
| | Multiple Myeloma | 9 | 2024 | 93 | 2.410 |
Why?
| | Hodgkin Disease | 4 | 2024 | 118 | 1.690 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 1360 | 1.680 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 72 | 1.660 |
Why?
| | Medical Oncology | 5 | 2024 | 230 | 1.590 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 524 | 1.560 |
Why?
| | Neoplasms | 4 | 2022 | 2114 | 1.150 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 194 | 1.040 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 862 | 0.950 |
Why?
| | Antibodies, Bispecific | 1 | 2023 | 33 | 0.890 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 46 | 0.820 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 135 | 0.820 |
Why?
| | Plasma Exchange | 1 | 2021 | 12 | 0.800 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 12 | 0.790 |
Why?
| | Vaccination | 2 | 2021 | 1209 | 0.790 |
Why?
| | Dexamethasone | 7 | 2024 | 315 | 0.770 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 120 | 0.770 |
Why?
| | Lymphoma, B-Cell | 2 | 2022 | 85 | 0.770 |
Why?
| | Internship and Residency | 2 | 2021 | 957 | 0.760 |
Why?
| | Psychosocial Support Systems | 1 | 2021 | 12 | 0.760 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 28 | 0.740 |
Why?
| | Hospice Care | 1 | 2024 | 186 | 0.740 |
Why?
| | Terminal Care | 1 | 2024 | 212 | 0.730 |
Why?
| | Drug Costs | 1 | 2020 | 91 | 0.680 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 28 | 0.680 |
Why?
| | Brain Neoplasms | 2 | 2017 | 979 | 0.660 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 70 | 0.660 |
Why?
| | Humans | 51 | 2024 | 115859 | 0.660 |
Why?
| | Internal Medicine | 1 | 2021 | 211 | 0.650 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 91 | 0.630 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 27 | 0.600 |
Why?
| | Quality of Life | 3 | 2024 | 2390 | 0.600 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 15 | 0.580 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 125 | 0.580 |
Why?
| | Oncologists | 1 | 2017 | 31 | 0.580 |
Why?
| | Mental Health Services | 1 | 2021 | 326 | 0.570 |
Why?
| | Neoplasm, Residual | 4 | 2024 | 105 | 0.560 |
Why?
| | Immunocompromised Host | 1 | 2018 | 197 | 0.540 |
Why?
| | Medicare | 2 | 2023 | 666 | 0.540 |
Why?
| | Lymphoma | 3 | 2023 | 177 | 0.540 |
Why?
| | Cyclophosphamide | 3 | 2022 | 218 | 0.530 |
Why?
| | Empathy | 1 | 2017 | 140 | 0.530 |
Why?
| | Cancer Survivors | 1 | 2019 | 203 | 0.520 |
Why?
| | Mental Health | 1 | 2021 | 571 | 0.510 |
Why?
| | Health Personnel | 1 | 2021 | 579 | 0.510 |
Why?
| | Health Services Accessibility | 1 | 2021 | 771 | 0.500 |
Why?
| | Students, Medical | 2 | 2021 | 280 | 0.480 |
Why?
| | Curriculum | 1 | 2020 | 856 | 0.470 |
Why?
| | Hematology | 3 | 2024 | 13 | 0.460 |
Why?
| | Bullying | 1 | 2014 | 22 | 0.460 |
Why?
| | Transplantation, Autologous | 3 | 2023 | 175 | 0.450 |
Why?
| | Healthcare Disparities | 1 | 2018 | 487 | 0.440 |
Why?
| | Mental Disorders | 1 | 2021 | 903 | 0.440 |
Why?
| | Physicians | 1 | 2021 | 777 | 0.430 |
Why?
| | Aged | 16 | 2024 | 19292 | 0.420 |
Why?
| | Oligopeptides | 2 | 2024 | 248 | 0.410 |
Why?
| | Pediatrics | 1 | 2020 | 985 | 0.410 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 577 | 0.400 |
Why?
| | Delivery of Health Care | 1 | 2018 | 847 | 0.390 |
Why?
| | Faculty, Medical | 1 | 2014 | 234 | 0.390 |
Why?
| | Education, Medical | 1 | 2014 | 225 | 0.370 |
Why?
| | Middle Aged | 15 | 2024 | 27078 | 0.370 |
Why?
| | Skin Neoplasms | 1 | 2017 | 760 | 0.340 |
Why?
| | Vincristine | 2 | 2021 | 96 | 0.340 |
Why?
| | Etoposide | 2 | 2021 | 149 | 0.340 |
Why?
| | Public Health Surveillance | 2 | 2020 | 61 | 0.330 |
Why?
| | Male | 19 | 2024 | 56103 | 0.330 |
Why?
| | Aged, 80 and over | 8 | 2024 | 6434 | 0.330 |
Why?
| | Information Dissemination | 2 | 2022 | 192 | 0.320 |
Why?
| | Doxorubicin | 2 | 2021 | 290 | 0.310 |
Why?
| | Neoplasm Staging | 3 | 2024 | 1177 | 0.300 |
Why?
| | Treatment Outcome | 7 | 2024 | 9163 | 0.300 |
Why?
| | Prognosis | 5 | 2024 | 3344 | 0.280 |
Why?
| | Adult | 12 | 2024 | 30814 | 0.280 |
Why?
| | Fatal Outcome | 2 | 2017 | 286 | 0.280 |
Why?
| | Databases, Factual | 2 | 2022 | 1137 | 0.270 |
Why?
| | Female | 16 | 2024 | 60070 | 0.260 |
Why?
| | Platelet Factor 4 | 2 | 2022 | 21 | 0.250 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1264 | 0.240 |
Why?
| | Disease Management | 2 | 2018 | 563 | 0.240 |
Why?
| | Young Adult | 6 | 2024 | 10508 | 0.240 |
Why?
| | Rituximab | 2 | 2023 | 149 | 0.240 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2206 | 0.240 |
Why?
| | Methotrexate | 2 | 2023 | 228 | 0.230 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 15 | 0.230 |
Why?
| | Geriatrics | 1 | 2024 | 69 | 0.220 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 57 | 0.220 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 378 | 0.220 |
Why?
| | Azacitidine | 1 | 2024 | 130 | 0.220 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 171 | 0.210 |
Why?
| | Hospices | 1 | 2024 | 83 | 0.210 |
Why?
| | Retrospective Studies | 7 | 2024 | 12615 | 0.210 |
Why?
| | Melphalan | 1 | 2022 | 29 | 0.210 |
Why?
| | Bortezomib | 1 | 2022 | 41 | 0.210 |
Why?
| | Watchful Waiting | 1 | 2022 | 57 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 71 | 0.200 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2022 | 30 | 0.200 |
Why?
| | Amyloidosis | 1 | 2022 | 36 | 0.200 |
Why?
| | Africa | 1 | 2022 | 99 | 0.200 |
Why?
| | Platelet Count | 1 | 2021 | 83 | 0.200 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 83 | 0.190 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 241 | 0.190 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 21 | 0.190 |
Why?
| | Sirolimus | 1 | 2022 | 192 | 0.190 |
Why?
| | Home Care Services | 1 | 2024 | 226 | 0.190 |
Why?
| | Sulfonamides | 1 | 2024 | 447 | 0.180 |
Why?
| | Prednisone | 1 | 2021 | 232 | 0.180 |
Why?
| | Health Occupations | 1 | 2020 | 30 | 0.180 |
Why?
| | Frailty | 1 | 2023 | 116 | 0.180 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 332 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2021 | 147 | 0.180 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 250 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2022 | 175 | 0.180 |
Why?
| | Survivorship | 1 | 2020 | 38 | 0.170 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4673 | 0.170 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 361 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 196 | 0.170 |
Why?
| | Personal Satisfaction | 1 | 2021 | 185 | 0.170 |
Why?
| | Botulism | 1 | 2019 | 4 | 0.170 |
Why?
| | Risk Factors | 4 | 2024 | 8715 | 0.160 |
Why?
| | Heroin Dependence | 1 | 2019 | 22 | 0.160 |
Why?
| | Medical Informatics | 1 | 2020 | 94 | 0.160 |
Why?
| | Program Development | 1 | 2021 | 350 | 0.160 |
Why?
| | Pandemics | 3 | 2022 | 1337 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2019 | 244 | 0.160 |
Why?
| | SEER Program | 1 | 2019 | 195 | 0.160 |
Why?
| | Needs Assessment | 1 | 2020 | 320 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 179 | 0.160 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 666 | 0.160 |
Why?
| | Machine Learning | 1 | 2021 | 320 | 0.160 |
Why?
| | Social Media | 1 | 2020 | 135 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 532 | 0.150 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 99 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 666 | 0.150 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 32 | 0.140 |
Why?
| | Narration | 1 | 2017 | 46 | 0.140 |
Why?
| | Symptom Assessment | 1 | 2018 | 121 | 0.140 |
Why?
| | Prednisolone | 1 | 2017 | 77 | 0.140 |
Why?
| | Immunotherapy | 1 | 2021 | 481 | 0.140 |
Why?
| | Vaccines | 1 | 2022 | 376 | 0.140 |
Why?
| | Program Evaluation | 1 | 2021 | 841 | 0.140 |
Why?
| | Research | 1 | 2020 | 398 | 0.140 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 551 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.140 |
Why?
| | Pilot Projects | 1 | 2021 | 1379 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 816 | 0.140 |
Why?
| | Survivors | 1 | 2019 | 404 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1088 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 193 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1127 | 0.130 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 225 | 0.130 |
Why?
| | Anxiety | 1 | 2021 | 854 | 0.120 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 991 | 0.110 |
Why?
| | Child | 3 | 2022 | 18537 | 0.110 |
Why?
| | Mutation | 1 | 2024 | 3371 | 0.110 |
Why?
| | Clinical Competence | 1 | 2020 | 924 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1758 | 0.110 |
Why?
| | Cytokines | 1 | 2021 | 1858 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2021 | 975 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 2911 | 0.110 |
Why?
| | Depression | 1 | 2021 | 1145 | 0.110 |
Why?
| | Adolescent | 3 | 2019 | 17935 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2019 | 1709 | 0.100 |
Why?
| | Registries | 1 | 2020 | 1772 | 0.100 |
Why?
| | Prevalence | 1 | 2018 | 2270 | 0.100 |
Why?
| | Colorado | 1 | 2021 | 4122 | 0.100 |
Why?
| | United States | 3 | 2024 | 12319 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2017 | 805 | 0.090 |
Why?
| | Recurrence | 2 | 2024 | 950 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1891 | 0.070 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 22 | 0.060 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 8 | 0.060 |
Why?
| | Lymphoma, T-Cell | 1 | 2024 | 21 | 0.060 |
Why?
| | Withholding Treatment | 1 | 2024 | 69 | 0.060 |
Why?
| | Thalidomide | 1 | 2024 | 28 | 0.060 |
Why?
| | Cytarabine | 1 | 2023 | 52 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2023 | 37 | 0.050 |
Why?
| | Imides | 1 | 2022 | 10 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2022 | 40 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 204 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 123 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 105 | 0.050 |
Why?
| | Biotin | 1 | 2022 | 20 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 102 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2023 | 177 | 0.050 |
Why?
| | Education, Premedical | 1 | 2021 | 4 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 381 | 0.050 |
Why?
| | Blogging | 1 | 2021 | 8 | 0.050 |
Why?
| | Professionalism | 1 | 2021 | 14 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2022 | 76 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1001 | 0.050 |
Why?
| | Central Nervous System | 1 | 2023 | 239 | 0.050 |
Why?
| | Heparin | 1 | 2022 | 227 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2023 | 352 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 342 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 685 | 0.040 |
Why?
| | Plasma | 1 | 2022 | 213 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 333 | 0.040 |
Why?
| | Writing | 1 | 2021 | 85 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2022 | 423 | 0.040 |
Why?
| | Dysphonia | 1 | 2019 | 11 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2022 | 277 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 53 | 0.040 |
Why?
| | Paraplegia | 1 | 2019 | 52 | 0.040 |
Why?
| | Muscle Weakness | 1 | 2019 | 81 | 0.040 |
Why?
| | Biomedical Research | 1 | 2024 | 589 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 151 | 0.040 |
Why?
| | Deglutition Disorders | 1 | 2019 | 119 | 0.040 |
Why?
| | Dyspnea | 1 | 2019 | 224 | 0.040 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 152 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 2336 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 285 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 2992 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 4960 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4447 | 0.020 |
Why?
|
|
Major's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|